LIXTE Biotechnology Holdings (NASDAQ: LIXT) has reported continued advancement of its lead oncology candidate, LB-100, in its first-quarter 2026 Form 10-Q filing, including expansion of its ovarian cancer trial following favorable safety findings in combination with immunotherapy. The company also noted growth at its recently acquired Liora Technologies Europe subsidiary as part of a broader strategic expansion to strengthen its oncology pipeline and treatment development capabilities.
LB-100, a first-in-class clinical PP2A inhibitor, has shown it is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma.
Through its wholly owned subsidiary Liora Technologies Europe Ltd., LIXTE is also pioneering the development of electronically controlled proton therapy systems for treating tumors. Liora’s proprietary LiGHT System is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. Additional information about Liora Technologies can be found at www.lioratechnologies.com.
The company’s strategic expansion comes as it continues to advance its oncology pipeline, with LB-100 at the forefront. The expansion of the ovarian cancer trial is particularly notable given the high unmet medical need in this indication. Ovarian Clear Cell Carcinoma is a rare but aggressive form of ovarian cancer with limited treatment options. If successful, LB-100 could offer a new therapeutic approach for these patients.
LIXTE’s novel approach is covered by a comprehensive patent portfolio. The company’s progress in the first quarter underscores its commitment to developing innovative cancer therapies. The filing of the Form 10-Q provides transparency into the company’s operations and milestones achieved during the period.
For more information about LIXTE Biotechnology Holdings, visit www.lixte.com. The latest news and updates relating to LIXT are available in the company’s newsroom at https://ibn.fm/LIXT.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is LIXTE Biotechnology Reports First-Quarter Progress on Oncology Pipeline, Expands Ovarian Cancer Trial.